How Will the Market React to Panbela Therapeutics Inc (PBLA) Stock Getting a Bearish Rating

Panbela Therapeutics Inc (PBLA) stock is down 1.74% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Panbela Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on PBLA!

See Full PBLA Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With PBLA Stock Today?

Panbela Therapeutics Inc (PBLA) stock is trading at $1.13 as of 10:07 AM on Friday, Oct 13, a rise of $0.06, or 5.61% from the previous closing price of $1.07. The stock has traded between $1.02 and $1.13 so far today. Volume today is light. So far 5,961 shares have traded compared to average volume of 55,751 shares. To see InvestorsObserver's Sentiment Score for Panbela Therapeutics Inc click here.

More About Panbela Therapeutics Inc

Panbela Therapeutics Inc is a clinical stage drug development company. It is engaged in the commercial development of a proprietary polyamine analogue for pancreatic cancer and for the second indication in chronic pancreatitis. The firm has developed a polyamine analogue compound referred as SBP-101 for the exocrine pancreas, with therapeutic potential for both pancreatic cancer and pancreatitis indications. Click Here to get the full Stock Report for Panbela Therapeutics Inc stock.